U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462377) titled 'A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC' on March 05.
Brief Summary: A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Epidermal Growth Factor
Epidermal Growth Factor Receptor
Epidermal Growth Factor Receptor Gene Mutation
Non Small Cell
Non Small Cell Lung
Non Small Cell Lung Cancer
Head and Neck
Head and Neck Canc...